Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
397.7 USD | -0.76% | +1.07% | -2.26% |
Apr. 25 | Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515 | MT |
Apr. 23 | Vertex Pharmaceuticals in T1D Licensing Pact With TreeFrog Therapeutics | DJ |
Official Publications
SEC Filing 10K | CO | |
SEC Filing 13G | CO | |
SEC Filing 13G | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 8K | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-3 | CO | |
Slide show Q3 | CO | |
3rd quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-2 | CO | |
Slide show half-year results | CO | |
1st-half-year results | CO | |
SEC Filing 8K | CO | |
SEC Filing 10Q-1 | CO | |
Slide show Q1 | CO | |
1st quarter results | CO | |
SEC Filing 8K | CO | |
SEC Filing 13G | CO | |
SEC Filing 10K | CO | |
SEC Filing 13G | CO | |
Slide show results | CO | |
Annual results | CO | |
SEC Filing 8K | CO |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Official Publications